Abstract 96P
Background
Flot (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is the standard regimen for perioperative chemotherapy in locally advanced gastric cancer. Preoperative chemotherapy downstages the tumor, increases pathological response. Patients receiving flot are hospitalised for more than a day. This study compares it with dox (docetaxel, oxaliplatin and capecitabine) - a daycare regimen, as capecitabine has already been proven non-inferior to 5-fluorouracil in advanced gastric cancer.
Methods
62 patients were enrolled in this prospective observational study. 31 patients received 4 doses of 2 weekly infusions of 5-fluorouracil- 2600 mg/m2, leucovorin - 200 mg/m2, oxaliplatin - 85 mg/m2, docetaxel- 50 mg/m2 on day 1. Rest 31 received 3 doses of 3 weekly infusions of docetaxel- 60 mg/m2, oxaliplatin - 130 mg/m2 on day 1 and tablet capecitabine -1000 mg/m2 bid for 14 days. Radiological response to chemotherapy were analysed 2 weeks after chemotherapy completion and categorised into stable disease, partial response, progressive disease and complete response according to recist criteria version 1.1. Chi-square test was applied for analysis.
Results
In flot arm, 38.1 % (8) had partial response, 66.7 % (12) had progressive disease, 55 % (11) had stable disease radiologically. In dox arm, 61.9 %(13) had partial response, 33.3 % (6) had progressive disease, 45 % (9) had stable disease radiologically . 3 patients in dox regimen did not have evaluation (1 lost to follow-up; 2 died during the course of treatment). P value obtained was 0.197. The radiological response to chemotherapy was not statistically significant between two groups.
Conclusions
The radiological response to chemotherapy post flot or dox regimen is not statistically different. Dox maybe considered as an alternative regimen to flot in neoadjuvant chemotherapy in locally advanced gastric cancer patients with the advantage being a daycare procedure, requiring less resources and manpower.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02